[HTML][HTML] Nicotine induces resistance to erlotinib therapy in non-small-cell lung cancer cells treated with serum from human patients
T Imabayashi, J Uchino, H Osoreda, K Tanimura… - Cancers, 2019 - mdpi.com
… lung cancer cell lines used in the present study, treatment with serum from smokers resulted
in a significant inhibition of the effects of erlotinib… in PC9 cells when compared to serum from …
in a significant inhibition of the effects of erlotinib… in PC9 cells when compared to serum from …
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
CTT Nguyen, F Petrelli, S Scuri, BT Nguyen… - The European Journal of …, 2019 - Springer
… After converting the currencies used in the studies to I$, using the CPI and PPP, we found
that erlotinib in the first-line treatment of advanced NSCLC had incremental cost-effectiveness …
that erlotinib in the first-line treatment of advanced NSCLC had incremental cost-effectiveness …
[HTML][HTML] A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
… and improve the diagnosis and treatment of erlotinib-resistant non-small cell lung cancer. …
In this study, we demonstrated that an erlotinib-based nanotheranostic agent successfully …
In this study, we demonstrated that an erlotinib-based nanotheranostic agent successfully …
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation
T Landre, G Des Guetz, K Chouahnia… - … of Cancer Research …, 2020 - Springer
… -cell lung cancer (NSCLC) represents 80% of lung cancers … -generation reversible EGFR
inhibitors, erlotinib and gefitinib; second-… The results of several exploratory studies showed the …
inhibitors, erlotinib and gefitinib; second-… The results of several exploratory studies showed the …
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc …
… alone in non-small-cell lung cancer (NSCLC). In this follow-up of the ENSURE study, we
evaluated progression-free survival (PFS) with first-line erlotinib followed by chemotherapy at …
evaluated progression-free survival (PFS) with first-line erlotinib followed by chemotherapy at …
[HTML][HTML] First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer
K Kishi, H Sakai, T Seto, T Kozuki, M Nishio… - … treatment and research …, 2019 - Elsevier
… The phase II JO28638 study evaluated first-line onartuzumab plus erlotinib in patients with …
-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The study …
-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The study …
[HTML][HTML] … nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
HA Jung, SY Woo, SH Lee, JS Ahn… - … Cancer Research, 2020 - ncbi.nlm.nih.gov
… Study subjects and data collection This study included 599 patients with EGFR-mutant
NSCLC who started first-line gefitinib, erlotinib, afatinib treatment for advanced NSCLC at …
NSCLC who started first-line gefitinib, erlotinib, afatinib treatment for advanced NSCLC at …
Nano-synergistic combination of Erlotinib and Quinacrine for non-small cell lung cancer (NSCLC) therapeutics–Evaluation in biologically relevant in-vitro models
… of anti-cancer efficacy in comparison to plain drug therapy. In this study, these reported …
The main aim of this study was to study the combinatorial effect of developed nanoparticles, …
The main aim of this study was to study the combinatorial effect of developed nanoparticles, …
… study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer
T Shimizu, K Nishio, K Sakai, I Okamoto… - Cancer chemotherapy …, 2020 - Springer
… -randomized, phase I study of YM155 in combination with erlotinib in patients with EGFR …
safety and tolerability of YM155 in combination with erlotinib and determine the DLT and MTD. …
safety and tolerability of YM155 in combination with erlotinib and determine the DLT and MTD. …
RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non–small cell lung cancer
…, M Reck, RELAY study investigators - … Cancer Research, 2021 - AACR
Purpose: In EGFR-mutated metastatic non–small cell lung cancer (NSCLC), outcomes from
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …